Stock Evaluator: Quantum BioPharma Ltd. (QNTM)

Quantum BioPharma Ltd. QNTM

$2.89 0.05 1.76%
July 31, 2026 4:00:00 PM EST November 10, 2021 Volume: 50,066
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Pharmaceuticals

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
Quantum BioPharma Ltd., together with its subsidiaries, operates as a biopharmaceutical company. The company operates through two segments, Biopharmaceutical Innovation and Strategic Investments. It researches and develops a portfolio of assets and biotech solutions for the treatment of neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. The company’s lead compound is Lucid-MS, a patented new chemical entity that is in Phase 2 clinical trial to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. It also develops FSD-PEA, which is in preparation for Phase 2 trial for the treatment of inflammatory diseases, such as mast cell activation syndrome; Lucid-PSYCH to treat major depressive disorder; and unbuzzd, a dietary supplement for the treatment of alcohol misuse. In addition, the company maintains a portfolio of strategic investments comprising loans secured by residential property. The company was formerly known as FSD Pharma Inc. and changed its name to Quantum BioPharma Ltd., in August 2024. Quantum BioPharma Ltd. was founded in 1998 and is based in Toronto, Canada.

Commentary & Analysis


Financial Summary

Share Statistics QNTM Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $18.5 $579.1 10%
Shares Out (Mil) 4.5 43.0 13%
Institutional Ownership 62.8% 84.3% 40%
Float (Mil) 6.0 46.8 14%
Beta 0.36 0.62 20%
Avg Daily Volume (000s) 90 285 35%
Price Change
(52-week)
(87.2%) 63.8% 5%
Growth QNTM Industry
Median
Percentile
(All Stocks)
Sales (5yr) na 6.7% na
Net Income (5yr) 3.8% (1.4%) 45%
EPS (5yr) 45.9% 14.9% 91
Dividends (5yr) na 0.0% na
Cash Flow (5yr) (15.1%) (14.9%) 51%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates na na na
Current EPS na na na
Month Ago EPS na na na
# Rev Up na na na
# Rev Down na na na
Three Months Ago EPS na na na
Year/Year Chg na na na
Financials QNTM Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) na $272 na
Net Income (TTM) (Mil) ($31) ($11) 20%
EPS (TTM) ($8.222) ($0.500) 5%
Operating Cash Flow (TTM) (Mil) ($6) ($6) 24%
Net Cash Flow (TTM) (Mil) $1 $4 46%
Long-Term Debt (Q1) (Mil) $0 $7 0%
Enterprise Value (Q1) (Mil) $38 $522 15%
Valuation QNTM Industry
Median
Percentile
(All Stocks)
P/B 29.10 2.73 97%
P/E na 20.5 na
Dividend Yield na 0.0% na
PEG (5yr hist) na 1.2 na
Ratios QNTM Industry
Median
Percentile
(All Stocks)
Gross Margin na 65.9% na
Net Margin na 0.7% na
ROA (209.1%) (24.6%) 2%
ROE (984.8%) (19.7%) 0%
Liabilities to Assets 109.5% 35.5% 95%
F-Score 1 3 1%

Quantum BioPharma Ltd. did not pass any screens on 7/31/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors